Further details

Table: Design characteristics of included trials (Posted as supplied by authors)

Coxib

Indication

Protocol number

Author, Year

Reference number

Sample size

Scheduled duration/weeks

Coxib dose, mg/day

NSAID comparator

Placebo*

















(coxib comparator)



Rofecoxib

Rheumatoid arthritis

68

Schnitzer 1999

1

658

104 (8 placebo)

25/50

Naproxen 500 mg bid

Yes





17





137

46 (6 placebo)

75/125/175

Ibuprofen 800 mg tid

Yes





96

van Adelsberg, 2002

2

909

52 (12 placebo)

12.5/25/50

Naproxen 500 mg bid

Yes





97

Geusens, 2002

3

1058

52 (12 placebo)

25/50

Naproxen 500 mg bid

Yes





098/103

Hawkey, 2003

4

660

12

50

Naproxen 500 mg bid

Yes





088/089

Bombardier, 2000

72

8076

36

50

Naproxen 500 mg bid

No





134

Goodman, 2004

75

132

64

3.25-25

Naproxen 15 mg/kg

No





135

Goodman, 2004

75

252

64

3.25-25

Naproxen 15 mg/kg

No



Osteoarthritis

10

Ehrich, 1999

5

219

6

25/125

NA

Yes





29

Ehrich, 2001

6

672

166 (6 placebo)

12.5/25/50

Diclofenac 75 mg bid

Yes





33

Saag, 2000

7

736

6

12.5/25

Ibuprofen 800 mg tid

Yes





34

Saag, 2000

7

693

52

12.5/25

Diclofenac 50 mg tid

No





35

Cannon, 2000

79

784

52

12.5/25

Diclofenac 50 mg tid

No





40

Day, 2000

8

809

6

12.5/25

Ibuprofen 800 mg tid

Yes





44

Laine, 1999

9

742

24

25/50

Ibuprofen 800 mg tid

Yes





45

Hawkey, 2000

10

775

24

25/50

Ibuprofen 800 mg tid

Yes





58

Truitt, 2001

11

341

130 (6 placebo)

12.5/25

Nabumetone 1500 mg od

Yes





83

Murphy 2003

12

305

60 (12 placebo)

25

Ibuprofen 800 mg tid

Yes





85

Kivitz, 2004

13

1042

6

12.5

Nabumetone 1000 mg od

Yes





90

Battisti, 2004

14

978

6

12.5

Nabumetone 1000 mg od

Yes





112





1521

6

12.5/25

(celecoxib 200 mg od)

Yes





116

Schnitzer, 2001

15

1477

6

25

(celecoxib 200 mg od)

Yes





136

Laine, 2004

16

1615

12

25

Ibuprofen 800 mg tid

Yes





901

Myllykangas-Luosujarvi, 2002

73

943

6

12.5

Naproxen 500 mg bid

No





902

Acevedo, 2001

80

909

6

12.5

Diclofenac 50 mg bid

No





102/903

Lisse, 2003

74

5557

12

25

Naproxen 500 mg bid

No





219

Birbara, 2004

19

395

6

12.5

(celecoxib 200 mg od)

Yes





220

Ruoff, 2004

20

413

6

12.5

(celecoxib 200 mg od)

Yes



Alzheimer’s



Aisen, 2003

21

351

52

25

Naproxen 220 mg bid

Yes





78

Thal, 2005

22

1451

208

25

NA

Yes





91

Reines, 2004

23

692

60

25

NA

Yes





126

Reicin A, 2003

24

756

60

25

NA

Yes



Low back pain

120

Katz, 2003

25

380

4

25/50

NA

Yes





121

Katz, 2003

25

310

4

25/50

NA

Yes



FAP

129





17

24

25

NA

Yes







Higuchi 2003

26

21

36

25

NA

Yes



Polyps

122

Bresalier, 2005

27

2586

144

25

NA

Yes



Migraine

125

Silberstein, 2004

28

172

12

25

NA

Yes



Prostatitis

118

Nickel, 2003

30

160

6

25/50

NA

Yes



Other

50

Hunt, 2000

29

67

4

25/50

Ibuprofen 800 mg tid

Yes





54





115

4

25

Indomethacin 75 mg od

Yes

Celecoxib

Rheumatoid arthritis

12

Simon, 1998

31

327

4

80/400/800

NA

Yes





22

Simon, 1999

32

1148

12

200/400/800

Naproxen 500 mg bid

Yes





23





1102

12

100/200/400

Naproxen 500 mg bid

Yes





41

Emery, 1999

81

655

26

400

Diclofenac 75 mg bid

No



Osteoarthritis

20

Bensen, 1999

33

1092

12

50/100/200

Naproxen 500 mg bid

Yes





21





1214

12

50/100/200

Naproxen 500 mg bid

Yes





42

McKenna, 2002

83

687

6

100

Diclofenac 50 mg bid

No





47





401

4

25/100/400

NA

Yes





54

Kivitz, 2001

34

1059

12

100/200/400

Naproxen 500 mg bid

Yes





60





684

6

100/200

NA

Yes





87

Williams, 2001

35

715

6

100/200

NA

Yes





96





13194

12

100/200

Diclofenac 50 mg bid

No

















Naproxen 500 mg bid







118

McKenna, 2001

36

598

6

100

Diclofenac 50 mg bid

Yes





152





123

6

200

(rofecoxib 25 mg od)

Yes





216





958

4

100

Loxoprofen 60 mg tid

Yes





0508-002

Sowers, 2005

76

404

12

200

Naproxen 500 mg bid

No

















(rofecoxib 25 mg od)







0508-003

Gibofsky, 2003

18

475

6

200

NA

Yes

















(rofecoxib 25 mg od)







0508-010

Pincus, 2004

37

353

6

200

NA

Yes





0508-249

Pincus, 2004

37

371

6

200

NA

Yes





1006





916

52

200

Diclofenac 50 mg bid

No





1051





317

6

200

Naproxen 500 mg bid

Yes





1052





362

6

200

Naproxen 500 mg bid

Yes





1053





316

6

200

Naproxen 500 mg bid

Yes





1063





386

6

200

Ibuprofen 800 mg tid

Yes



OA/RA

035_102

Silverstein, 2000

86

7968

52

800

Ibuprofen 800 mg tid

No

















Diclofenac 75 mg bid







62





536

12

200

Naproxen 500 mg bid

No





71





1097

12

200

Diclofenac 75 mg bid

No

















Ibuprofen 800 mg tid







105





666

12

100

Diclofenac 50 mg bid

No





106





125

12

100

Diclofenac 50 mg bid

No





107





89

12

100

Diclofenac 50 mg bid

No







Chan, 2002

87

287

24

400

Diclofenac 75 mg bid

No







Palmer, 2003

40

385

4

400

Nabumetone 1000 mg bid

Yes

















Ibuprofen 800 mg tid









Izhar, 2004

84

25

4

200

Diclofenac 75 mg bid

No



Alzheimer’s

1





425

52

200

NA

Yes



Disease

2





36

156

200

NA

Yes



Low back pain

0508-244





360

12

200

NA

Yes





0508-245





374

12

200

NA

Yes





0508-269





790

12

200

NA

Yes





217





881

12

200

Loxoprofen 60 mg tid

No



FAP



Phillips, 2002

41

83

24

200/800

NA

Yes



Polyps

APC 005

Solomon, 2005

42

2035

156

400/800

NA

Yes





PreSAP 016

Levin, 2005

43

1561

156

400

NA

Yes



TMJ pain



Ta, 2004

44

68

6

200

Naproxen 500 mg bid

Yes



Ankylosing spondylitis

137

Dougados, 2001

45

245

6

100

Ketoprofen 100 mg bid

Yes





193





611

12

200/400

Naproxen 500 mg bid

Yes

Etoricoxib

Rheumatoid arthritis

10

Curtis, 2003

49

581

174 (8 placebo)

60/90/120

Diclofenac 50 mg tid

Yes





24

Matsuomoto, 2002

50

816

121 (12 placebo)

90/120

Naproxen 500 mg bid

Yes





25

Collantes, 2002

51

891

121 (12 placebo)

90/120

Naproxen 500 mg bid

Yes





26

Hunt, 2003

52

560

12

120

Naproxen 500 mg bid

Yes





36

Tsoukas, 2001

53

102

6

90

NA

Yes



Osteoarthritis

7

Gottesdiener, 2002

54

617

190 (6 placebo)

30/60/90

Diclofenac 50 mg tid

Yes





18

Reginster, 2004

55

496

138 (12 placebo)

60

Naproxen 500 mg bid

Yes





19

Leung, 2002

56

501

138 (12 placebo)

60

Naproxen 500 mg bid

Yes





26

Hunt, 2003

57

182

12

120

Naproxen 500 mg bid

Yes





29

Hunt, 2003

57

680

12

120

Ibuprofen 800 mg tid

Yes





805

Zacher, 2003

88

516

6

60

Diclofenac 50 mg tid

No





61

Baraf, 2004

89

7111

52

90

Diclofenac 50 mg tid

No





71

Wiessenhutter 2005

58

528

12

30

Ibuprofen 800 mg tid

Yes





73





548

12

30

Ibuprofen 800 mg tid

Yes























Ankylosing spondylitis

32

Van der Heijde 2005

59

387

52 (6 placebo)

90/120

Naproxen 500 mg bid

Yes



Back pain

41

Pallay, 2004

60

325

12

60/90

NA

Yes





42

Birbara, 2003

38

319

12

60/90

NA

Yes



Other

27

Hunt, 2003



62

4

120

Ibuprofen 800 mg tid

Yes





65

DiBattiste, 2004

46

433

12

90

Ibuprofen 800 mg tid

Yes

















(celecoxib 200 mg bid)



Lumiracoxib

Rheumatoid arthritis

105

Schnitzer, 2005

61

570

4

100/200/400

Diclofenac 75 mg bid

Yes





110

Kivitz, 2004



893

13

400/800

Ibuprofen 800 mg tid

No

















(celecoxib 200 mg bid)







114





937

13

200/400

(celecoxib 200 mg bid)

Yes





111

Geusens, 2004

62

1124

26

200/400

Naproxen 500 mg bid

Yes





2312

Scott, 2003

78

120

4

800/1200

Naproxen 500 mg bid

No





2335

Pavelka, 2004

63

1151

52 (13 placebo)

200

Naproxen 500 mg bid

Yes



Osteoarthritis

117

Farkouh, 2004

77

9471

52

400

Naproxen 500 mg bid

No





2332

Farkouh, 2004

77

8773

52

400

Ibuprofen 800 mg tid

No





104

Schnitzer, 2004

64

583

4

50/100/200/400

Diclofenac 75 mg bid

Yes





2316

Benevolenskaya, 2003

65

244

4

100

NA

Yes





2319

Grifka, 2004

66

594

4

200/400

NA

Yes





109

Berenbaum, 2005

17

1600

13

200/400

(celecoxib 200 mg od)

Yes





112

Tannenbaum, 2004

39

1702

13

200/400

NA

Yes

















(celecoxib 200 mg od)







126

Hawkey, 2004

85

1042

13

200/400

Ibuprofen 800 mg tid

No

















(celecoxib 200 mg od)







128

Berenbaum, 2005

17

511

13

400

NA

Yes

















(rofecoxib 25 mg od)







2360

Sheldon, 2005

47

1551

13

100

NA

Yes

















(celecoxib 200 mg)







2361

Lehman, 2005

48

1684

13

100

(celecoxib 200 mg)

Yes

Valdecoxib

Rheumatoid arthritis/

15





640

6

Oct-20

Naproxen 500 mg bid

Yes



Osteoarthritis

16





678

6

05/10/2020

Naproxen 500 mg bid

Yes





48

Sikes, 2002

67

1051

12

Oct-20

Ibuprofen 800 mg tid

Yes

















Diclofenac 75 mg bid







49

Makarowski, 2002

68

466

12

05-Oct

Naproxen 500 mg bid

Yes





53

Kivitz, 2002

69

1016

12

05/10/2020

Naproxen 500 mg bid

Yes





60

Bensen, 2002

70

1089

12

10/20/40

Naproxen 500 mg bid

Yes





61





1093

12

10/20/40

Naproxen 500 mg bid

Yes





4





341

6

20

(rofecoxib 25 mg)

Yes





62

Pavelka, 2003

90

720

26

20/40

Diclofenac 75 mg bid

No





63





782

52

Oct-20

Diclofenac 75 mg bid

No





47





1217

26

20/40

Naproxen 500 mg bid

No



Low back pain

97





256

4

40

NA

Yes





108

Coats, 2004

71

293

4

40

NA

Yes





132





456

12

20/40

NA

Yes





133





485

12

Oct-20

NA

Yes



Cancer pain

40





235

12

40

NA

Yes





79





183

6

20

Diclofenac 75 mg bid

Yes

NA= Not applicable

















*Trials with a placebo arm are indicated by a yes

Excludes patients who did not start treatment: 39 allocated to lumiracoxib, 24 to naproxen and 18 to ibuprofen.





Fig A
. Comparison of effects of different COX 2 inhibitors versus placebo, subdivided by daily dose of each individual drug (posted as supplied by the authors)



 



 

 Fig B. Comparison of effects of different COX 2 inhibitors versus placebo, subdivided by regular aspirin use at trial entry (posted as supplied by the authors)



 



Web reference list (posted as supplied by the authors)

w1. Schnitzer TJ, Truitt K, Fleischmann R, Dalgin P, Block J, Zeng Qet al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999;21:1688-702.

w2. van Adelsburg J, Truitt KE, De Tora LM, Anderson M, Fabriele M, Chen PYet al. One-year results from an active comparator-controlled trial of rofecoxib in patients with rheumatoid arthritis (RA). Arthritis Rheum 2002;1: S336-S337.

w3. Geusens PP, Truitt K, Sfikakis P, Zhao PL, DeTora L, Shingo Set al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol 2002;31:230-8.

w4. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut 2003;52:820-6.

w5. Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman Met al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group. J Rheumatol 1999;26:2438-47.

w6. Ehrich EW, Bolognese JA, Watson DJ, Kong SX. Effect of Rofecoxib Therapy on Measures of Health-Related Quality of Life in Patients With Osteoarthritis. Am J Manag Care 2001;7:609-16

w7. Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese Jet al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000;9:1124-34.

w8. Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir Met al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. Arch Intern Med 2000;160:1781-7.

w9. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz Het al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999;117:776-83.

w10. Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado-Cocco J, Acevedo Eet al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Arthritis Rheum 2000;43:370-7.

w11. Truitt KE, Sperling RS, Ettinger WH Jr, Greenwald M, DeTora L, Zeng Qet al. A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis. Aging (Milano) 2001;13:112-21.

w12. Murphy G, DeTora L, Lee M, Gertz B. Effects of rofecoxib and ibuprofen on bone mineral density (BMD) and biochemical indices of bone turnover in patients with osteoarthritis. Ann Rheum Dis 2003;62(Suppl. 1): Abstract FRI0226.

w13. Kivitz AJ, Greenwald MW, Cohen SB, Polis AB, Najarian DK, Dixon MEet al. Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004;52:666-74.

w14. Battisti WP, Katz NP, Weaver AL, Matsumoto AK, Kivitz AJ, Polis ABet al. Pain management in osteoarthritis: a focus on onset of efficacy-a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials. J Pain 2004;5:511-20.

w15. Schnitzer TJ , Kivitz AJ, Greenwald M, Fleischmann RM, Matzura-Wolfe D, Polis ABet al. Rofecoxib provides superior relief of symptoms of osteoarthritis (OA) compared to celecoxib. EULAR, Prague. Ann Rheum Dis 2001;60:236.

w16. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402.

w17. Berenbaum F, Grifka J, Brown JP, Zacher J, Moore A, Krammer Get al. Efficacy of lumiracoxib in osteoarthritis: a review of nine studies. J Int Med Res 2005;33:21-41.

w18. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003;48:3102-11.

w19. Birbara C, Sheldon E, Farrell J, Rodgers A, Petruschke, R Robertson, D et al. Comparable efficacy of rofecoxib 12.5mg and celecoxib 200mg in the treatment of patients with osteoarthritis: a randomized, controlled trial. Ann Rheum Dis 2004; 63(Suppl. 1):Abstract FRI0432.

w20. Ruoff G, Gilderman L, Cohen S, Valenzuela C, Rodgers A, Petruschke Ret al. Treatment of osteoarthritis patients with rofecoxib 12.5 mg and celecoxib 200mg: A randomized, placebo-controlled trial. Presented at Osteoarthritis Research Society International 2004 ;Abstract P215:118.

w21. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KLet al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.

w22. Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen Eet al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-15.

w23. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CRet al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62:66-71.

w24. Reicin A, Dibattiste P, Mukhopadhyay S, Korn S, Ramey D, Lines C et al. Cardiovascular safety of rofecoxib in elderly patients with Alzheimer's disease or cognitive impairment: an updated pooled analysis. Ann Rheum Dis 2003;62(Suppl.1):407.

w25. Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJet al. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine 2003;28:851-8.

w26. Higuchi T, Iwama T, Yoshinaga K, Toyooka M, Taketo MM, Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 2003;9:4756-60.

w27. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan Ket al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.

w28. Silberstein S, Tepper S, Brandes J, Diamond M, Goldstein J, Winner P et al. Randomised, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004;62:1552-1557.

w29. Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola Aet al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-6.

w30. Nickel JC, Pontari M, Moon T, Gittelman M, Malek G, Farrington Jet al. A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. J Urol 2003;169:1401-5.

w31. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BDet al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.

w32. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RCet al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.

w33. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EMet al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.

w34. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JBet al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467-79.

w35. Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23:213-27.

w36. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.

w37. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz Ret al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9.

w38. Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NRet al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability--a randomized, placebo-controlled, 3-month trial. J Pain 2003;4:307-15.

w39. Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor Get al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004;63:1419-26.

w40. Palmer R, Weiss R, Zusman RM, Haig A, Flavin S, MacDonald B. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135-9.

w41. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BPet al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.

w42. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn Pet al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.

                    w43. Levin B. Celecoxib in adenoma prevention – the PreSAP Trial. Slide presentation at: Meeting of

the FDA Advisory Committee on COX-2 Inhibitors and NSAIDS; February 16-18, 2005; Gaithersburg, MD. Available at: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1_09_FDA-Levin.ppt (accessed 2 Dec 2005).

w44. Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004;111:13-21.

w45. Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri Iet al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.

w46. DiBattiste PM, Chen C, Viscusi J, Curtis SP, Cannon CP. Etoricoxib has no adverse effects on biomarkers of cardiovascular risk in patients with osteoarthritis. J Am Coll Cardiol 2004;43:511A.

w47. Sheldon E, Beaulieu A, Paster Z, Dutta D, Yu S, Sloan VS. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005;27:64-77.

w48. Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston Het al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005;21:517-26.

w49. Curtis SP, Losada B, Bosi-Ferraz M, Saenz R, Miller ER, Ray Pet al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. Arthritis Rheum 2003;48(9, Suppl.):S124-S125.

w50. Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PLet al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30.

w51. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian Aet al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002;3:10.

w52. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans Jet al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.

w53. Tsoukas C, Eyster E, Mukhpadhyay S, Giallells K. Efficacy of etoricoxib in the treatment of hemophilic arthropathy. Arthritis Rheum 2001;44:S124-S124.

w54. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko Aet al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41:1052-61.

w55. Reginster JY , Fischer CL, Beaulieu A, Malmstrom K, Curtis SP, Miller ERet al. Etoricoxib demonstrates similar efficacy and improved gastrointestinal safety compared to naproxen in two 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis 2004;63:Abstract FRI0394.

w56. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu Aet al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58.

w57. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee Met al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.

w58. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BAet al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:470-9.

w59. van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff Met al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.

w60. Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz Ret al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33:257-66.

w61. Schnitzer TJ, Gitton X, Jayawardene S, Sloan VS. Lumiracoxib in the treatment of osteoarthritis, rheumatoid arthritis and acute postoperative dental pain: results of three dose-response studies. Curr Med Res Opin 2005;21:151-61.

w62. Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis Get al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004;58:1033-41.

w63. Pavelka K, Nayiager S, Kivitz A, Patel N, Yu S, Sloan V. Efficacy and tolerability of lumiracoxib in the treatment of rheumatoid arthritis: A 13-week, randomized, double-blind study. Ann Rheum Dis 2004;63:280 (Abstract FRI0107).

w64. Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber Iet al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;51:549-57.

w65. Benevolenskaya L, Tuzun S, Hagin E, Moore A, Gimona A. Lumiracoxib is effective in relieving symptoms of knee or hip osteoarthritis after 4 weeks of treatment: results from a randomized, placebo-controlled trial. Ann Rheum Dis 2003;62:270 (Abstract FR10246).

w66. Grifka JK, Zacher J, Brown JP, Seriolo B, Lee A, Moore Aet al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004;22:589-96.

w67. Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.

w68. Makarowski W, Zhao WW, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002;10:290-6.

w69. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002;51:530-7.

w70. Bensen W, Weaver A, Espinoza L, Zhao WW, Riley W, Paperiello Bet al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology (Oxford) 2002;41 :1008-16.

w71. Coats TL, Borenstein DG, Nangia NK, Brown MT. Effects of valdecoxib in the treatment of chronic low back pain: results of a randomized, placebo-controlled trial. Clin Ther 2004;26:1249-60.

w72. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis Bet al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.

w73. Myllykangas-Luosujarvi R, Lu HS, Chen SL, Choon D, Amante C, Chow CTet al. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trals of six weeks duration. Scand J Rheumatol 2002;31 :337-44.

w74. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CSet al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539-46.

w75. Goodman S, Ferrandiz M, Kiss MH, St Rose E, Chen PY, Frontera Net al. Rofecoxib demonstrates long-term safety and tolerability in juvenile rheumatoid arthritis (JRA). Arthritis Rheum 2004;50:S94-S95.

w76. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer Net al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.

w77. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJet al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.

w78. Scott G, Rordorf C, Milosavljev S, Chase W, Fleischmann RM, and Kivitz AJ. Multiple-dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics , 124 (Abstract P-197). 2003. Springer-Verlag. In Tulunay FC, Orme M editors.

w79. Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese Jet al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87.

w80. Acevedo E, Castaneda O, Ugaz M, Beaulieu AD, Pons-Estel B, Caeiro Fet al. Tolerability profiles of rofecoxib (Vioxx) and Arthrotec. A comparison of six weeks treatment in patients with osteoarthritis. Scand J Rheumatol 2001;30:19-24.

w81. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead Het al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.

w82. Kivitz AJ, Nayiager S, Schimansky T, Gimona A, Thurston HJ, Hawkey C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther 2004;19:1189-98.

w83. McKenna F, Arguelles L, Burke T, Lefkowith J, Geis GS. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002;20:35-43.

w84. Izhar M, Alausa T, Folker A, Hung E, Bakris GL. Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004;43:573-7.

w85. Hawkey CC, Svoboda P, Fiedorowicz-Fabrycy IF, Nasonov EL, Pikhlak EG, Cousin Met al. Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 2004;31:1804-10.

w86. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton Aet al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.

w87. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VKet al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-10.

w88. Zacher J, Feldman D, Gerli R, Scott D, Hou SM, Uebelhart Det al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003;19:725-36.

w89. Baraf H, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer Bet al. Tolerability and effectiveness of etoricoxib compared to diclofenac sodium in patients with osteoarthritis: a randomized controlled study (EDGE trial). Arthritis Rheum 2004;50:S346-7.

w90. Pavelka K, Recker DP, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 2003;42:1207-15.